GET DAILY SIGNALSBioCardia (BCDA): Can the Stock Reach the $15.50 Target for +1,585% Upside?
Key Takeaways
- The central target of $15.50 is the arithmetic mean of two verified analyst price targets: $6.00 from Alliance Global Partners and $25.00 from H.C. Wainwright.
- The latest verified price is about $0.92, meaning the target implies a required upside of roughly 1,585% — an exceptionally large move.
- The analyst range is unusually wide — from $6 to $25 — reflecting deep disagreement about the company's regulatory and clinical outlook.
- The strongest supporting factors are recent regulatory progress on the Helix catheter and CardiAMP programs in the U.S. and Japan.
- The biggest risks are a lack of meaningful revenue, ongoing net losses, and dependence on clinical and regulatory milestones that have not yet been achieved.
- For more on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- To see how AI-driven tools evaluate opportunities across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Coverage of BCDA is thin, which is common for micro-cap biotechnology companies. Two firms publish current targets. H.C. Wainwright analyst Joseph Pantginis maintains a Buy rating and a $25 target, reaffirmed in August 2026, citing regulatory momentum in the Helix catheter and CardiAMP heart-failure programs. Alliance Global Partners analyst James Molloy reiterates a Buy rating with a $6 target, last affirmed in May 2026.
Averaging these two figures produces a mean of $15.50, with an approximate low-to-high range of $6 to $25. The width of that range is itself informative: the higher target reflects optimism about a full regulatory and commercial pathway, while the lower figure prices in far more modest progress. This is not an official published consensus, and a mean of just two data points should be read with caution rather than as a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent close near $0.92, BCDA sits well below its 52-week high of $1.80 and modestly above its 52-week low of $0.75. Reaching $15.50 would require a gain of roughly 1,585% — an exceptionally large move that would transform a company with a market capitalization of only about $14 million into one valued at more than $230 million.
A path of that magnitude is not driven by ordinary quarterly execution. It would likely require a sequence of binary, high-impact events: successful clinical data, regulatory clearances for the Helix delivery system and CardiAMP, and a commercial launch. Each of these carries substantial execution and scientific risk for a clinical-stage company with essentially no product revenue.
What Could Support a Move Toward the Target
Several verifiable developments have strengthened the bull case. In October 2026, the company announced that the U.S. FDA accepted its pre-submission package for the Helix catheter, a delivery device intended for therapeutic and diagnostic agent delivery. In early November, BioCardia completed a clinical consultation with Japan's PMDA for the CardiAMP Cell Therapy System, advancing toward a marketing approval application in that market. The company has also indicated that its ongoing CardiAMP Heart Failure II trial may support a PMA (premarket approval) submission.
Insider activity offers a modest but notable signal, with CEO Peter Altman making a series of small open-market purchases during 2026. A low beta of roughly 0.65 also means the stock has historically shown less sensitivity to broad market swings than typical equities, though this does little to reduce its company-specific risk. From what I see, using Tickeron’s AI Trend Prediction Engine helped confirm the potential impact of these catalysts on price movement.
What Could Prevent the Target From Being Reached
The obstacles are substantial. BioCardia generates essentially no product revenue, reported a trailing net loss of about $7.3 million, and held roughly $4.1 million in cash in its most recent quarter. Dilutive financing remains a recurring risk for micro-cap biotechs, and prior history includes at-the-market offerings and warrant activity.
Regulatory and clinical outcomes are inherently uncertain. Acceptance of a submission is not approval, and pivotal trial data must still demonstrate both safety and efficacy. Even a favorable outcome may not justify a valuation dozens of times higher than today's level if commercialization proves slow or further capital raises dilute existing shareholders.
Technical Levels and Market Structure
The stock has been in a broad downtrend from its multi-year peaks, trading below long-term moving averages. The $1.00 round-number level and the $1.80 52-week high represent notable resistance zones, while $0.75 marks a durable support level near the 52-week low. Any move toward $15.50 would first require a sustained break back above $1.00 and then a reclamation of the $1.80 high — a multi-step process rather than a single catalyst.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms do not always state an explicit timeframe, and the two targets here imply sharply different trajectories. Investors should watch the company's quarterly results and updates, including the Q3 2026 report and conference call scheduled for November 12, 2026, the FDA's substantive review of the Helix catheter submission, Japanese regulatory progress on CardiAMP, and any CardiAMP clinical data readouts. Financing announcements and analyst revisions will also matter for a cash-constrained company.
Exploring AI Daily Buy/Sell Signals
In my research process for names like this, I often rely on Tickeron’s AI Daily Buy/Sell Signals to get a systematic view. These tools use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The service is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For those tracking a volatile, event-driven name like BCDA, such tools can provide an additional layer of signal alongside fundamental research.
Final Assessment
The $15.50 central target is best understood as the midpoint between two very different analyst views, not a probable outcome. From roughly $0.92, the required upside of about 1,585% is enormous, and the gap between the $6 and $25 targets reveals genuine uncertainty about the company's future. Regulatory momentum on the Helix catheter and CardiAMP programs provides a credible foundation for optimism, while the absence of revenue, ongoing losses, and binary clinical risk argue for caution. Reaching the target would require a near-perfect sequence of clinical and regulatory successes — possible, but far from assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BCDA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BCDA turned positive on November 10, 2026. Looking at past instances where BCDA's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCDA's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 64 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on BCDA as a result. In 86 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in 183 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
BCDA moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCDA crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for BCDA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BCDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.766) is normal, around the industry mean (3.498). P/E Ratio (-1.441) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage regenerative medicine company, which develops novel therapeutics for cardiovascular diseases
Industry Biotechnology
Advertisement